Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2017’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)

The report reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Leishmaniasis (Kala-Azar) therapeutics and enlists all their major and minor projects

The report assesses Leishmaniasis (Kala-Azar) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

BioLingus AG

Daiichi Sankyo Co Ltd

iCo Therapeutics Inc.

Laboratorios LETI SL

ManRos Therapeutics

Matinas BioPharma Holdings Inc

Merck & Co Inc

Mologen AG

Nanomerics Ltd

Novartis AG

Oblita Therapeutics BVBA

Sequella Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Leishmaniasis (Kala-Azar) - Overview 10

Leishmaniasis (Kala-Azar) - Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Pipeline by Universities/Institutes 15

Products under Development by Companies 17

Products under Development by Universities/Institutes 19

Leishmaniasis (Kala-Azar) - Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 29

BioLingus AG 29

Daiichi Sankyo Co Ltd 29

iCo Therapeutics Inc. 29

Laboratorios LETI SL 30

ManRos Therapeutics 30

Matinas BioPharma Holdings Inc 31

Merck & Co Inc 31

Mologen AG 31

Nanomerics Ltd 32

Novartis AG 32

Oblita Therapeutics BVBA 33

Sequella Inc 33

Leishmaniasis (Kala-Azar) - Drug Profiles 34

(gentamicin sulfate + paromomycin sulfate) - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

18-MC - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

amphotericin B - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

amphotericin B - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

amphotericin B - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

amphotericin B - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Amphotericin B sodium - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

candicidin - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CDRI-99288 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CpGD-35 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

D-121 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

DI-4G - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

DNDI-6148 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

GNF-6702 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

hypoestoxide - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

interferon gamma - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

KVH-14 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

leishmaniasis vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

leishmaniasis vaccine - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

leishmaniasis vaccine - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

leishmaniasis vaccine - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

leishmaniasis vaccine - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

MGN-1331 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

MT-2002 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

NPC-1161B - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

P-MAPA - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Peptides for Infectious Diseases - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

S-015-2344 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecule for Leishmaniasis - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Small Molecules 1 for Visceral Leishmaniasis - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Small Molecules for Infectious Diseases - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecules for Infectious Diseases - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecules for Leishmaniasis - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Small Molecules for Leishmaniasis - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Small Molecules for Leishmaniasis - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Small Molecules for Trypanosomiasis - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Small Molecules for Visceral Leishmaniasis - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecules for Visceral Leishmaniasis - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecules to Inhibit LHR1 for Leishmaniasis - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecules to Inhibit MmpL3 for Infectious Diseases - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

Synthetic Peptides for Infectious Disease - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Vaccine for Leishmaniasis - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

visceral leishmaniasis vaccine - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

Leishmaniasis (Kala-Azar) - Dormant Projects 95

Leishmaniasis (Kala-Azar) - Discontinued Products 97

Leishmaniasis (Kala-Azar) - Product Development Milestones 98

Featured News & Press Releases 98

Nov 01, 2017: MOLOGEN: Grant of US$ 2.6 million for further development of vaccine 98

Nov 28, 2016: iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program 98

Aug 08, 2016: A single compound could treat three parasitic diseases 99

Dec 15, 2015: U.S. Issues Patent on Corifungin 100

Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 100

Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 100

Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014 101

Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 101

Feb 26, 2013: National Institutes of Health Supports Acea’s Research 102

Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis 102

Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee 103

Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 104

Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 105

Jul 01, 2011: FDA issues orphan-drug designation to Corifungin 106

Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 106

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108

List of Tables

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2017 11

Number of Products under Development by Companies, H2 2017 13

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Universities/Institutes, H2 2017 15

Products under Development by Companies, H2 2017 17

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18

Products under Development by Universities/Institutes, H2 2017 19

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 20

Number of Products by Stage and Target, H2 2017 22

Number of Products by Stage and Mechanism of Action, H2 2017 24

Number of Products by Stage and Route of Administration, H2 2017 26

Number of Products by Stage and Molecule Type, H2 2017 28

Leishmaniasis (Kala-Azar) – Pipeline by BioLingus AG, H2 2017 29

Leishmaniasis (Kala-Azar) – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 29

Leishmaniasis (Kala-Azar) – Pipeline by iCo Therapeutics Inc., H2 2017 30

Leishmaniasis (Kala-Azar) – Pipeline by Laboratorios LETI SL, H2 2017 30

Leishmaniasis (Kala-Azar) – Pipeline by ManRos Therapeutics, H2 2017 30

Leishmaniasis (Kala-Azar) – Pipeline by Matinas BioPharma Holdings Inc, H2 2017 31

Leishmaniasis (Kala-Azar) – Pipeline by Merck & Co Inc, H2 2017 31

Leishmaniasis (Kala-Azar) – Pipeline by Mologen AG, H2 2017 32

Leishmaniasis (Kala-Azar) – Pipeline by Nanomerics Ltd, H2 2017 32

Leishmaniasis (Kala-Azar) – Pipeline by Novartis AG, H2 2017 33

Leishmaniasis (Kala-Azar) – Pipeline by Oblita Therapeutics BVBA, H2 2017 33

Leishmaniasis (Kala-Azar) – Pipeline by Sequella Inc, H2 2017 33

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2017 95

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2017 (Contd..1), H2 2017 96

Leishmaniasis (Kala-Azar) – Discontinued Products, H2 2017 97

List of Figures

List of Figures

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Number of Products under Development by Universities/Institutes, H2 2017 15

Number of Products by Top 10 Targets, H2 2017 21

Number of Products by Stage and Top 10 Targets, H2 2017 21

Number of Products by Top 10 Mechanism of Actions, H2 2017 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 25

Number of Products by Stage and Routes of Administration, H2 2017 25

Number of Products by Molecule Types, H2 2017 27

Number of Products by Stage and Molecule Types, H2 2017 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports